Klinik Psikiyatri Dergisi - Turkish Journal of Clinical Psychiatry is a distinguished open-access journal dedicated to the evolving field of psychiatry and mental health. Published by KLINIK PSIKIYATRI DERGISI in Turkey since 1998, this journal aims to provide a platform for the dissemination of research, clinical studies, and reviews that contribute to the understanding of psychological disorders and treatment methodologies. With an ISSN of 1302-0099 and an E-ISSN of 2146-7153, the journal is indexed in various databases, although it currently holds a rank of 460/567 in the Scopus ranking for the category of Medicine: Psychiatry and Mental Health. The journal operates under an open-access model, ensuring that research findings are readily accessible to a wide audience, contributing to greater knowledge and awareness in the field. As it converges from 2017 to 2024, Klinik Psikiyatri Dergisi continues to strive for excellence, providing valuable insights and resources for researchers, professionals, and students interested in the complexities of mental health.

JOURNAL OF ADDICTIVE DISEASES, published by ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, serves as a pivotal platform for researchers, clinicians, and students in the realms of clinical psychology, psychiatry, and addiction studies. With a distinguished history dating back to its inception in 1991, this journal spans critical research developments with its current scope covering converged years from 2018 to 2024, ensuring a robust repository of knowledge. Notably, it holds a respectable impact factor and is categorized in Q2 quartiles across several disciplines including Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health for 2023, reflecting its impactful contributions to the scientific community. Despite the journal not currently offering Open Access, it remains highly ranked, occupying positions in the top percentiles of Scopus rankings. This journal emphasizes the importance of disseminating high-quality research focused on addictive behaviors and diseases, thereby addressing vital clinical and public health challenges.

Current Addiction Reports, published by SPRINGERNATURE, is a leading journal dedicated to the comprehensive study of addiction in its various dimensions, with a particular focus on the latest clinical developments and research in Clinical Psychology and Psychiatry and Mental Health. Since its inception in 2014 and through to 2024, the journal has established itself as a pivotal resource for researchers, professionals, and students alike, currently holding a prestigious Q1 ranking in both relevant categories. With an impressive Scopus rank of #46 in Clinical Psychology and #129 in Psychiatry and Mental Health, it occupies a significant position within the field, reflecting its commitment to high-quality scholarship and impactful findings. The journal offers open access options, ensuring that vital research is readily available to a global audience. By fostering a deeper understanding of addiction trends and innovative treatment methodologies, Current Addiction Reports plays an essential role in advancing knowledge and improving clinical practices.

Middle East Current Psychiatry (MECPsych), published by SpringerNature, is a prominent open-access journal dedicated to advancing the field of psychiatry and mental health in the Middle East and beyond. Since its establishment in 2011, MECPsych has aimed to disseminate high-quality research, reviews, and reports that capture recent developments in psychiatric science, clinical practice, and public health considerations in mental well-being. With an impact factor reflective of its growing influence and classified in the Q3 quartile for Psychiatry and Mental Health, the journal offers invaluable insights backed by rigorous peer review processes. Operating under an open access model since 2019, MECPsych ensures that its articles are freely accessible to a global readership, enhancing the visibility and application of research findings. As part of its ongoing commitment to enriching understanding in the field, MECPsych also encourages submissions that explore the unique cultural, societal, and economic factors influencing mental health across the region. This approach not only supports researchers, professionals, and students in their pursuit of knowledge but also fosters a collaborative dialogue among mental health stakeholders in the Middle East and around the world.

Advances in Dual Diagnosis, published by EMERALD GROUP PUBLISHING LTD, serves as a vital resource for professionals and researchers in the fields of psychiatry and mental health. With an ISSN of 1757-0972 and E-ISSN 2042-8324, this journal has been at the forefront of dual diagnosis research since its inception in 2008, aiming to bridge the gap in knowledge and practice regarding the co-occurrence of mental health disorders and substance use issues. Rated in the Q4 category for Psychiatry and Mental Health, it ranks 31st out of 45 in Nursing and Psychiatric Mental Health and 408th out of 567 in Medicine and Psychiatry, providing a unique platform for showcasing emerging research, innovative treatment strategies, and case studies that enhance understanding of complex patient needs. While the journal is not openly accessible, its contributions are crucial for driving forward the academic discourse and practical applications surrounding dual diagnosis. As we look to the future through 2024 and beyond, the Advances in Dual Diagnosis journal continues to strive for excellence in disseminating knowledge that benefits practitioners and scholars alike.

DRUG AND ALCOHOL REVIEW, published by Wiley, is a leading journal dedicated to advancing the scholarship in the fields of drug and alcohol research. Since its inception in 1989, this esteemed publication has provided a critical platform for the dissemination of innovative research findings, reviews, and theoretical papers, addressing pressing issues in substance use and addiction. With an impact factor that places it in the Q1 category in both Health (social science) and Medicine (miscellaneous), it ranks #78 out of 371 in the Scopus index for Health and #115 out of 398 in Medicine, reflecting its significant influence and high citation rates among scholars. The journal is committed to fostering a multidisciplinary approach, integrating perspectives from psychology, sociology, public health, and medicine, to inform policy and practice. Accessible to researchers and practitioners alike, *DRUG AND ALCOHOL REVIEW* serves as an essential resource for anyone invested in understanding and addressing the complexities of drug and alcohol use in society.

Canadian Journal of Addiction is a leading platform dedicated to advancing the understanding of addiction and its multifaceted impacts on individuals and society. Published by LIPPINCOTT WILLIAMS & WILKINS, this journal aims to foster rigorous research and discussion in the field of addiction studies, contributing significantly to the intersection of psychiatry and mental health. With its ISSN 2368-4720 and E-ISSN 2368-4739, the journal is indexed in Scopus and has been categorized in the Q3 quartile for 2023, reflecting its emerging influence amongst peers. The Canadian Journal of Addiction facilitates a vital exchange of ideas and findings, crucial for researchers, practitioners, and students alike, addressing pressing issues related to addiction through innovative studies and insightful reviews. Subscribers and readers benefit from the latest findings as they navigate through the dynamic landscape of addiction research, enriching both academic knowledge and practical applications.

Welcome to the Journal of Addiction Medicine, a premier academic resource devoted to the field of addiction studies, published by LIPPINCOTT WILLIAMS & WILKINS. Since its inception in 2007, this esteemed journal has become a leader in disseminating groundbreaking research, with impressive rankings in the Q1 quartile across key disciplines such as Medicine (Miscellaneous), Pharmacology (Medical), and Psychiatry and Mental Health, reflecting its significance in the scholarly community. With an ISSN of 1932-0620 and an E-ISSN of 1935-3227, it caters to a diverse audience of researchers, clinicians, and students seeking to expand their understanding of addiction medicine. The journal's articles are primarily published in a non-open access format, ensuring high-quality research is accessible through institutional subscriptions. With a Scopus ranking that positions it within the top tiers of several relevant categories, the Journal of Addiction Medicine is essential for anyone committed to advancing knowledge in the field and addressing the complexities surrounding addiction.

JOURNAL OF SUBSTANCE ABUSE TREATMENT, published by Pergamon-Elsevier Science Ltd, is a leading peer-reviewed journal that spans a wide range of topics related to substance abuse and addiction treatments. With an impressive impact factor, this esteemed journal ranks in the Q1 quartile across multiple disciplines including Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health, making it a vital resource for researchers and practitioners alike. Covering convergence years from 1984 to 2023, it publishes cutting-edge research that informs treatment methodologies and policy development in the field of substance abuse. With access options that adapt to both traditional and modern academic needs, the journal seeks to advance the understanding and effectiveness of substance abuse treatment through comprehensive studies and innovative approaches. Be part of a global dialogue that shapes the future of addiction treatment by engaging with the latest findings and expert analyses that help bridge the gap between research and clinical practice.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.